AUTHOR=Pawinska-Wasikowska Katarzyna , Czogala Malgorzata , Skoczen Szymon , Surman Marta , Rygielska Monika , Ksiazek Teofila , Pac Agnieszka , Wieczorek Aleksandra , Skalska-Sadowska Jolanta , Samborska Magdalena , Wachowiak Jacek , Chaber Radoslaw , Tomaszewska Renata , Szczepanski Tomasz , Zielezinska Karolina , Urasinski Tomasz , Moj-Hackemer Malgorzata , Kalwak Krzysztof , Kozlowska Marta , Irga-Jaworska Ninela , Balwierz Walentyna , Bukowska-Strakova Karolina 

TITLE=Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children—the Polish Pediatric Leukemia and Lymphoma Study Group experience

JOURNAL=Frontiers in Immunology

VOLUME=Volume 14 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1268993

DOI=10.3389/fimmu.2023.1268993

ISSN=1664-3224

ABSTRACT=Background: Gemtuzumab ozogamicin (GO), one of the first targeted drug used in oncology, consists of an anti-CD33 monoclonal antibody bound to a derivative of cytotoxic calicheamicin. After the drug withdrawn in 2010 due to a significantly higher rate of early deaths, GO regained approval in 2017 for the treatment of newly diagnosed, refractory, or relapsed acute myeloid leukemia (AML) in adults and children over 15 years of age. The objective of the study was a retrospective analysis of clinical characteristics, treatment outcomes, and GO toxicity profile in children with primary refractory or relapsed AML (R/R) treated in Poland from 2008 to 2022.